Company Overview
Gossamer Bio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of seralutinib for treating pulmonary hypertension and pulmonary arterial hypertension within the United States market. The company functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, where it focuses on advancing therapeutic candidates through clinical research phases. This biopharmaceutical organization employs a workforce of 161 individuals and maintains a current market capitalization of $81.32M while reporting trailing twelve-month revenue of $48.47M. These valuation and revenue figures indicate that Gossamer Bio occupies a small-cap position relative to large pharmaceutical peers, suggesting a stage of growth where capital efficiency is critical before achieving profitability. The business description highlights the development of GB002, an inhaled small molecule utilizing platelet-derived growth factors, which underscores the company's reliance on proprietary asset development rather than established product sales.
Financial Health
Gossamer Bio reported annual revenue of $48.47M over the trailing twelve months, yet this generated a net income of -$170,370,000, revealing a significant gap that points to substantial cost structures inherent in clinical-stage operations. The company also recorded an EBITDA of -$163,228,992, further illustrating that operating expenses, likely driven by research and development activities, far exceed current revenue generation. Free cash flow stands at -$93,332,248, indicating that the company is burning cash to fund its operations and pipeline advancement rather than generating liquidity from daily business activities. Despite these negative cash flows, the firm holds $136.93M in cash against $202.91M in debt, creating a net debt position that requires careful management of future financing needs. The balance sheet reflects a high level of leverage, evidenced by the absence of a debt-to-equity ratio in standard reporting and the significant debt burden relative to cash holdings. Margins provide a stark picture of the company's current profitability status, with a gross margin of 100.0% typical for a pre-revenue or early-revenue stage before cost of goods sold scales, an operating margin of -333.6% reflecting heavy overhead, and a profit margin of 0.0% due to the net loss. Return on Equity is not available due to the negative equity position, while Return on Assets sits at -41.9%, demonstrating that management is currently utilizing assets to generate negative returns. The current ratio is reported at 2.64, which suggests the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer despite the overall negative cash flow situation.
Valuation Assessment
Valuation metrics for Gossamer Bio present a complex picture due to the lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -1.84, implying that the market is pricing the stock based on future expectations rather than historical earnings. The price-to-book ratio is listed at -0.66, which indicates that the market is valuing the company below its book value in negative terms, a common characteristic for biotechnology firms with high debt loads or significant intangible assets not fully captured on the balance sheet. Alternative valuation multiples such as the price-to-sales ratio of 1.68 and an EV/EBITDA of -0.90 suggest that investors are focusing on revenue potential and pipeline value rather than current earnings power. The stock's trading range over the last 52 weeks spans from a low of $0.33 to a high of $3.87, placing the current valuation within a highly volatile band relative to its historical extremes. The beta value of 2.11 indicates that the stock exhibits more than double the volatility of the broader market, meaning price swings will be amplified compared to large-cap benchmarks.
Growth & Income
Revenue growth for the company is reported at 47.1% year-over-year, while earnings growth is listed as N/A, implying that the business is prioritizing top-line expansion through new indications or market penetration rather than immediate profit generation. Since the company reports a net loss, the concept of dividend yield and payout ratio does not apply, resulting in a dividend yield of N/A and a payout ratio of 0.0%. Consequently, Gossamer Bio reinvests all available earnings, or rather, all available capital, back into the company's operations and research initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by strong revenue acceleration paired with a total absence of dividend income, typical for clinical-stage biopharmaceuticals focused on long-term product development.